Kornimate/medical-research-clean huggingface dataset:
observational prospectif monocentric registry of patients suffering from vie

Conditions: Venous Thromboembolic Disease

Summary: patients with an episode of vte (dvt and / or pe) have a mortality rate of 16-21% at 1 year after diagnosis. morbidity associated with vte is marked by the risk of recurrence, estimated at 30% and estimated at 29% after 8 years of follow post-thrombotic syndrome. for a number of these patients, risk factors have been identified (congenital or acquired thrombophilia, cancer, postpartum, surgery, prolonged immobilization, etc..). in 25-50% of cases, the etiology remains unknown, justifying the need for well-conducted studies to determine other potential risk factors. in addition, the expansion of treatment options with the arrival on the market of new direct oral anticoagulants, allows comparative studies on the effectiveness and frequency of adverse events for each treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of venous thromboembolism established by a validated test (venous doppler ultrasound of the lower limbs, pulmonary angiography, lung scan ventilation / perfusion), * diagnosis of venous thromboembolism made within 15 days, * the previous inclusion in the register (outpatient or inpatient) exclusion criteria: * person doesn't wish to participate in this study

Keywords: venous thromboembolic pulmonary embolism
a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of mk8245 (8245-004)(completed)

Conditions: Type 2 Diabetes

Summary: a 2-period crossover study to assess the safety, tolerability and glucose-lowering effects of mk8245.

hypothesis: multiple doses of mk-8245 are sufficiently safe and well tolerated in patients with type 2 diabetes based on an assessment of clinical and laboratory adverse experiences (aes), to permit continued clinical investigation.

Eligibility criteria:
inclusion criteria: * subject has a diagnosis of type 2 diabetes and is being treated with diet and exercise alone or a single oral anti-hyperglycemic agent * subject is willing to follow the weight-maintaining diet and exercise program or equivalent beginning 4 weeks before receiving study drug, throughout the study and until the post study visit * subject has been a nonsmoker and/or has not used nicotine-containing products for at least approximately 6 months exclusion criteria: * subject has a history of stroke, chronic seizures, or major neurological disorder * subject has a history of neoplastic disease (except non-melanomatous skin carcinoma, carcinoma in situ of the cervix, other malignancies successfully treated at least 10 years prior to screening, or malignancies deemed highly unlikely to recur.) * subject has a history of type 1 diabetes mellitus and/or history of ketoacidosis * subject has a history of contact lens use within approximately the previous 6 months * subject has been diagnosed with dry eye syndrome * subject has used lipid-lowering therapies in the past 3 months (subjects on a stable monotherapy dose of statins may be included) * subject has had major surgery, donated or lost 1 unit of blood or participated in another investigational study within 4 weeks of starting in the study
study comparing fish oil and krill oil

Conditions: Inflammation; Dyslipidemia

Summary: eicosapentaenoic acid (epa) and docosahexaenoic acid (dha) are omega-3 fatty acids found in fish oil and in krill oil. the purpose of this study is to compare the effects of the recommended dose of a fish oil supplement (omax3 4:1 epa:dha; recommended daily dose 1650 mg - totaling 1500 mg epa+dha) and a krill oil supplement (megared; recommended daily dose 300 mg - totaling 74 mg epa+dha) on omega-3 index, plasma biomarkers of inflammation and inflammatory cell activation, and plasma lipid levels in subjects with metabolic syndrome.

inflammation plays a pivotal role in the pathogenesis of several chronic diseases including cardiovascular disease and diabetes mellitus. there has been some evidence that fish oil, containing the omega-3 fatty acids eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), reduces the risk or severity of these diseases, leading several government and health organizations to advocate an increased consumption of fish or fish oil. fish oil contains epa and dha either as triglycerides or as ethyl esters. recently, krill oil has gained popularity as an epa and dha supplement. krill oil contains epa and dha in phospholipid, triglyceride, and free fatty acid form. some studies have shown that the bioavailability of epa and dha in krill oil is higher than in fish oil and that smaller doses of krill oil are therefore sufficient to observe a significant effect on the desired outcome (inflammation, plasma lipid levels). the central hypothesis of this proposal is that the dose of the epa and dha omega-3 fatty acids is more important than their bioavailability in effecting changes in systemic inflammation and lipid metabolism.

Eligibility criteria:
inclusion criteria: * fasting plasma triglyceride levels between 150 and 500 mg/dl * c-reactive protein (crp) levels ≥2 µg/ml * at least one of the following criteria for the definition of metabolic syndrome: abdominal obesity (waist circumference \>40 inches in men and \>35 inches in women), hypertension (blood pressure ≥130/≥85 mmhg or use of anti-hypertensive medications), and fasting glucose ≥110 mg/dl. exclusion criteria: * high-fish diets (\>2 fish meals/week) * taking fish oil supplements or supplements containing epa or dha * regular use of anti-inflammatory medications * above normal coagulation time or use of anticoagulant medications * allergy to fish, fish oil, or shellfish * uncontrolled thyroid dysfunction * insulin-dependent type 2 diabetes mellitus * kidney or liver disease * smoking * drinking more than 7 alcoholic drinks/week * use of lipid-lowering medications or medications known to alter lipoprotein metabolism

Keywords: fish oil epa dha krill oil metabolic syndrome
examine the prognostic role of flt pet/ct for patients with lr-npc treated by carbon ion therapy

Conditions: Recurrent Nasopharyngeal Carcinoma

Summary: we aim, in this study, to examine whether reduction of flt pet derived suv before and after carbon ion radiotherapy can predict the treatment response and survivals for patients with locoregionally recurrent nasopharyngeal carcinoma.

this is a single-arm phase ii clinical trial evaluating the prognostic value of flt pet/ct for patients with locoregionally recurrent nasopharyngeal carcinoma. all patients will receive flt pet/ct scans before and after carbon ion radiotherapy (cirt). the sensitivity and specificity of reduction of flt uptake reduction in terms of predicting the treatment outcome evaluated by mri at 3 months after completion of cirt according to recist 1.1. its predictive value of os, lpfs, rpfs and dmfs will be examined as well.

Eligibility criteria:
inclusion criteria: * pathologically confirmed as primary nasopharyngeal carcinoma; * with recurrence at nasopharynx and/or recurrent retropharyngeal lymph node, recurrence was diagnosed by imaging or pathology studies; * already received one course of definitive radiation therapy, at least 6 months ago; * able to receive contrast mri scan and pet/ct scan; * ecog: 0-2; * anticipated survival time \>= 12 months; * with sufficient major organ functions; * willing to sign informed consent. exclusion criteria: * metal implants that might significantly influence the radiation dose distribution; * dose constrains for organs-at-risk are beyond acceptable limit; * with comorbidities/conditions that might influence the effectiveness of carbon-ion therapy; * pregnant or within lactation period; * drug/alcohol addiction; * with mental disorder that might impede the completion of therapy.

Keywords: flt pet/ct carbon ion radiation therapy re-irradiation
fatigue in systemic lupus erythematosus

Conditions: Fatigue; Systemic Lupus Erthematosus

Summary: the aim of this study is to investigate the effects of biopsychosocial status, quality of life, functional status and hematological markers on fatigue in individuals with sle.


Eligibility criteria:
inclusion criteria: * being diagnosed with sle according to the 2019 acr/eular diagnostic criteria * being 18 years of age or older exclusion criteria: * not being able to speak or understand turkish fluently * having a psychiatric illness that will affect cooperation * heart failure or lung pathology that will affect daily life activities * additional autoimmune disease
neuromuscular electrical stimulation and ultrasound therapies , knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: to determine the effects of ultrasound therapy and neuromuscular electrical stimulation on the muscle architecture and functional capacity of patients with knee osteoarthritis.

all participants who were satisfied with the inclusion criteria were randomly assigned to one of two study groups: group 1- ultrasound therapy group; group 2 - the neuromuscular electrical stimulation group. group allocation was randomized in two blocks of 30 sealed envelopes without external marks, which were mixed and numbered from 1 to 30, containing a piece of paper with the group allocation. the researchers responsible for outcome measures and ultrasonograhic measurements were blinded to the patients' diagnosis or intervention.

Eligibility criteria:
1. inclusion criteria: clinical diagnosis of knee osteoarthritis 2. exclusion criteria: cardiovascular diseases inflammatory diseases infectious diseases lower extremity weakness tumoral diseases knee surgery in the past six months intra-articular injection in the past six months

Keywords: knee osteoarthritis neuromuscular electrical stimulation ultrasound therapy
pain reduction using neurostimulation study

Conditions: End Stage Kidney Disease; Chronic Pain

Summary: this is a 4-year project to see if a small battery-powered, device attached to a headband, that sits on the skin surface and delivers what is a hardly noticeable level of electrical stimulation can reduce pain in patients who receive hemodialysis on an ongoing basis.

this is a 4-year r01 project to conduct a randomized controlled trial to evaluate the efficacy of an at-home transcranial direct current stimulation (tdcs) device to mitigate pain in persons receiving hemodialysis (hd) on account of end-stage kidney disease (eskd). pain is a highly common and morbid condition among persons with eskd requiring hd. because the current method of managing pain in this population typically involves the use of analgesic medications that confer substantial health risks, novel non-drug therapies are needed to reduce pain and lessen reliance on opioid and other drug therapies. the investigators will undertake a randomized controlled trial to determine the efficacy of an at-home neuromodulatory device to mitigate pain and improve other salient outcomes (e.g., mood, quality of life) in a stratified sample of hispanic or latino(a), black or african american, and non-hispanic white eskd patients requiring hd. however, no individuals will be excluded based on race/ethnicity

Eligibility criteria:
inclusion criteria: patients: * age ≥ 21 years * diagnosis of end stage kidney disease (ocd 18.6) and receiving hemodialysis * montreal cognitive assessment (moca-blind) adjusted score of≥18; * pain for ≥3 months, with a self-reported pain intensity of ≥4 (on a 0-10 scale) during the week preceding the screening; * speaks english or spanish * medically stable, as determined by clinician and defined as unlikely to undergo a substantial change in illness or treatment during the next 3 months * able to provide written informed consent. caregivers: * age ≥21 years * serves as primary caregiver for eskd patient (e.g., partner, adult child, friend) * speaks english or spanish exclusion criteria: * active medical or major psychiatric illnesses that will impact pain or interfere with study procedures * history of head trauma, seizure disorder, brain surgery, stroke, or cancer affecting head, metal implants in the head, or compromised skin integrity on the head in the area where electrodes will be placed * use of another neurostimulation device (such as spinal cord stimulator, cardio-stimulator implanted cardioverter-defibrillator) * not able to respond to brief questionnaires and rating scales that will interfere with study procedures * does not tolerate tdcs at a skin test (performed at training visit 2) * does not provide informed consent exclusion criteria for all above groups: \* does not speak english or spanish

Keywords: dialysis transcranial direct current stimulation (tdcs)
pharmacokinetic and safety study with adalimumab in chinese subjects with mild rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: pharmacokinetic and safety study with adalimumab in chinese subjects with mild rheumatoid arthritis


Eligibility criteria:
inclusion criteria: * male or female ages 18 years and older. * mild ra. * body weight less than 100 kg. exclusion criteria: * wheelchair-bound or bedridden. * joint surgery involving joints to be assessed within this study, within two months prior to the screening visit. * intra-articular, intramuscular or intravenous (iv) administration of corticosteroids within 28 days prior to the screening visit. * prior treatment with any tnf antagonist, including adalimumab. * positive tuberculin ppd 5. * female subjects who are pregnant or breast-feeding. * history of hiv or of being immuno-compromised. * history of malignancy. * poorly controlled medical condition.
wallflex biliary fully covered (fc) chronic pancreatitis study

Conditions: Biliary Stricture

Summary: the purpose of this of this study is to compare the use of self expanding metal stents (sems) to plastic stents for the treatment of benign biliary strictures secondary to chronic pancreatitis as it pertains to stricture resolution rates, complication rates and number of endoscopic retrograde cholangiopancreatography (ercp) procedures during 24 months. statistical testing will be performed to determine if the rate of stricture resolution for the metal stent is non-inferior to the plastic stent group.


Eligibility criteria:
inclusion criteria: * age 18 or older * willing and able to comply with the study procedures and provide written informed consent to participate in the study * chronic pancreatitis * symptomatic bile duct stricture (defined by cholangitis or persistent jaundice for at least one month or cholestasis associated with at least 3 times normal alkaline phosphatase levels) documented at time of enrollment for naïve stricture or at the time of prior plastic stent placement in strictures that had one prior plastic stent inserted.12 * common bile duct stricture based on imaging assessment of dilatation of the common and/or intrahepatic bile ducts exclusion criteria: * biliary stricture of benign etiology other than chronic pancreatitis * prior biliary metal stent or any plastic stenting other than one plastic stent of 10 fr or less for 6 months or fewer * developing obstructive biliary symptoms associated with an attack of acute pancreatitis * biliary stricture of malignant etiology * stricture within 2 cm of common bile duct bifurcation * known bile duct fistula or leak * subjects for whom endoscopic techniques are contraindicated * known sensitivity to any components of the stent or delivery system * symptomatic duodenal stenosis (with gastric stasis) * participation in another investigational study within 90 days prior to consent * investigator discretion

Keywords: benign biliary strictures secondary to chronic pancreatitis
clinical outcome of arthroscopic lateral release for lateral patellar compression syndrome

Conditions: Knee Pain Chronic

Summary: we performed a prospective case series study of 48 patients who suffered lateral patellar compression syndrome who were diagnosed by clinical examination and confirmed by m.r.i. and failed conservative management and underwent isolated arthroscopic lateral patellar retinaculum release in erbil teaching hospital, par private hospital and hawler private hospital between december 2016 and august 2019.


Eligibility criteria:
inclusion criteria: * lateral patellar compression syndrome proved by clinical,mri and arthroscopic examination exclusion criteria: 1. dislocated or history of dislocation. 2. patellar instability. 3. bony abnormality (trochlear groove hypoplasia or flat). 4. osteoarthritis of the knee 3rd and 4th grades. 5. infected knee. 6. varus and valgus knee. 7. rotational deformity of the lower extremity. 8. miserable malalignment triad. 9. anterior cruciate ligament, posterior cruciate ligament and medial collateral ligament rupture. 10. history of fracture around knee. 11. focal osteoarthritis of the lateral facet joint. 12. chondral lesion (outerbridge 3 and 4).

Keywords: lateral patellar compression syndrome arthroscopic lateral release lysholm score
study of genes and the environment in patients with endometrial cancer in the east anglia, oxford, trent, or west midlands regions of the united kingdom

Conditions: Endometrial Cancer

Summary: rationale: studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with endometrial cancer.

objectives: * to obtain epidemiological information and biological material on a population-based series of endometrial cancer cases. * to define the proportion of endometrial cancer incidence attributable to mutations in known predisposing genes such as msh2 and mlh1. * to determine the risk associated with these predisposing mutations by examining the cancer risk in relatives of patients who are shown to be carriers. * to examine the effect of nongenetic risk factors in mutation carriers. * to determine the pathological and clinical characteristics of endometrial cancers occurring in mutation carriers as compared with that in noncarriers. * to establish whether mutations at other loci may predispose to endometrial cancer by comparing the frequency of alterations in endometrial cancer patients with the corresponding frequency in cancer-free controls identified through the european prospective investigation of cancer (epic) study. outline: this is a multicenter study. patients complete an epidemiological questionnaire. the questionnaire will request identifying information about the patient's first-degree relatives. blood samples are collected from patients. dna is extracted from these blood samples and from samples collected from cancer-free control participants in mrec-search-control as well as from additional controls through the european prospective investigation of cancer (epic) study (a population based study of diet and health based in norfolk, east anglia). dna samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes. in addition to the endometrial cancer patients recruited for this study, patients with breast, ovarian, prostate, colorectal, bladder, kidney, pancreatic, brain and esophageal cancer, malignant melanoma, and lymphoma cancer are recruited in the following related clinical trials: mrec-search-breast, mrec-search-ovarian, mrec-search-prostate, mrec-search-colorectal, and mrec-search-cancer.

Eligibility criteria:
disease characteristics: * diagnosis of endometrial cancer within the past 5 years * identified in any of the following geographic regions of the united kingdom: * east anglia * oxford * trent * west midlands patient characteristics: * identified by the patient's general practitioner as fit to contact for this study * no serious mental illness or retardation prior concurrent therapy: * not specified

Keywords: endometrial cancer
eva-hip, evaluation of rehabilitation after hip-fracture

Conditions: Hip Fracture

Summary: to evaluate the effect on gait and activity of a home based physiotherapy intervention 4-6 months after the fracture. the investigators hypothesis is that exercises performed after the initial rehabilitation, which focuses on specific components of gait control will improve gait and increase level of activity.


Eligibility criteria:
inclusion criteria: * home dwelling prior to fracture * age\>70yr * able to walk 10m exclusion criteria: * expected life expectancies \<3 months * exercises contraindicated due to medical conditions
the benefits of deep neuromuscular block and sugammadex in laparoscopic colorectal surgery

Conditions: Colorectal Cancer

Summary: pneumoperitoneum, the use of carbon dioxide, presents some disadvantages, including a risk of hypercarbia and respiratory acidosis during surgery in the respiratory system, and of an increased mean arterial pressure and systemic vascular resistance due to sympathetic excitation in the cardiovascular system. 10\~15 mmhg intra-abdominal pressure is required in order to achieve a pneumoperitoneum, and increased abdominal pressure following a pneumoperitoneum causes hemodynamic changes leading to a reduced cardiac function by increasing the left ventricular end systolic wall stress and the right and left ventricular filling pressure, while decreasing the stroke volume and cardiac index. the author compared the intra-abdominal pressure necessary to achieve a pneumoperitoneum under deep muscle relaxation and medium muscle relaxation in ten patients undergoing laparoscopic surgery for colorectal cancer as part of preliminary research. the results showed that deep muscle relaxation, compared to medium muscle relaxation, was able to lower the intra-abdominal pressure by an average of 5.6 mmhg (13.2 ± 0.8 vs 7.6 ± 1.1) and the inspiratory pressure by an average of 8. above all, even after lowering the intra-abdominal pressure with deep muscle relaxation, the surgeon was able to maintain a view almost identical to the one afforded by medium muscle relaxation. however, up until now, no reports have clearly indicated the change in pneumoperitoneum pressure, the patient's hemodynamic change, post-operative recovery, and surgical prognosis depending on the depth of muscle relaxation.against this background, this study aims to identify the degree to which intra-abdominal pressure in laparoscopic colorectal surgery can be reduced by deep muscle relaxation, and the corresponding advantages this method presents in terms of physiological changes such as hemodynamic and respiratory system changes. in addition, the study intends to examine the difference between deep muscle relaxation and medium muscle relaxation in terms of surgical prognosis, including their effects on post-operative pain and on the patient's recovery of intestinal mobility.


Eligibility criteria:
inclusion criteria: * patients aged 19 to 80 scheduled to undergo laparoscopic colorectal or rectal surgery below the asa class 3 exclusion criteria: * patients with neuromuscular disease/patients with a personal history or family history of malignant hyperthermia/patients with a serious heart, kidney (gfr \ 100)/ patients who have had colorectal or rectal surgery/obese patients (bmi ≥35)

Keywords: deep neuromuscular block sugammadex laparoscopic colorectal surgery hemodynamic change